NDAORALTABLET
Approved
Dec 2017
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
STEGLATRO (ertugliflozin) by Merck & Co. is 2 diabetes mellitus: ertugliflozin, a sglt2 inhibitor, and metformin hydrochloride, a member of the biguanide class. Approved for type 2 diabetes mellitus. First approved in 2017.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STEGLATRO (ertugliflozin) is an oral SGLT2 inhibitor approved by the FDA in December 2017 for the treatment of type 2 diabetes mellitus. It works by inhibiting the SGLT2 transporter in the kidneys, thereby reducing renal glucose reabsorption and increasing urinary glucose excretion to lower blood glucose levels. The product is often used as monotherapy or in combination with other antidiabetic agents, positioning it within the modern diabetes treatment paradigm that emphasizes cardiovascular and renal benefits alongside glycemic control.
$0.0BPart D
4.2 years to LOEMechanism of Action
2 diabetes mellitus: ertugliflozin, a SGLT2 inhibitor, and metformin hydrochloride, a member of the biguanide class. Ertugliflozin SGLT2 is the predominant transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation. Ertugliflozin is an inhibitor of…
Indications (1)
Worked on STEGLATRO at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.